Protalix BioTherapeutics, Inc.
PLX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001006281
No open-market purchases or sales by Protalix BioTherapeutics, Inc. insiders were filed in the last 90 days; 101 institutions reported holding it in 13F filings for Q2 2026, worth $33.7M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Protalix BioTherapeutics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Of which not filed for Q1 2022 | Q1 2022 | Change |
|---|---|---|---|---|
| Holders | 31 | 1 | 32 | +2 |
| Shares | 2.94M | 14.5K | 1.22M | −1.71M (−58.3%) |
| Value | $2.45M | $12.1K | $1.29M | −$1.15M (−47.1%) |
1 institution that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (9)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Meitav Dash Investments Ltd | 244,332 | $257.0K | 0.00% |
| Bridgeway Capital Management, LLC | 28,790 | $31.0K | 0.00% |
| Renaissance Technologies LLC | 11,900 | $13.0K | 0.00% |
| Smith, Salley & Associates | 12,048 | $13.0K | 0.00% |
| Aptus Capital Advisors, LLC | 11,451 | $12.0K | 0.00% |
| Barclays PLC | 2,000 | $2.00K | 0.00% |
| JPMorgan Chase & Co | 1,127 | $1.00K | 0.00% |
| American Portfolios Advisors | 500 | $530 | 0.00% |
| Citigroup Inc | 300 | $0 | 0.00% |
Sold out (7)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Commonwealth Equity Services, LLC | 40,290 | $33.0K |
| Citadel Advisors LLC | 29,015 | $24.0K |
| Gsa Capital Partners LLP | 24,527 | $20.0K |
| Cutler Group LP | 10,067 | $8.00K |
| Migdal Insurance & Financial Holdings Ltd. | 2,432 | $2.00K |
| Rinkey Investments | 100 | $0 |
| Snowden Capital Advisors LLC | 500 | $0 |
Not filed for Q1 2022 yet (1)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q4 2021 and haven't filed a 13F for Q1 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Finivi Inc. | 14,544 | $12.1K |